Get the Stockscreener App
9.48
1.61%
0.15
After Hours:
9.45
-0.03
-0.32%
Omeros Corp stock is traded at $9.48, with a volume of 2.61M.
It is up +1.61% in the last 24 hours and down -22.61% over the past month.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
See More
Previous Close:
$9.33
Open:
$9.34
24h Volume:
2.61M
Relative Volume:
1.78
Market Cap:
$686.12M
Revenue:
-
Net Income/Loss:
$84.01M
P/E Ratio:
11.07
EPS:
0.856
Net Cash Flow:
$-101.16M
1W Performance:
-4.91%
1M Performance:
-22.61%
6M Performance:
+8.16%
1Y Performance:
+181.31%
1-Day Range:
$8.86
$9.88
1-Week Range:
$6.7023
$10.48
52-Week Range:
$2.95
$17.65
Omeros Corp Stock (OMER) Company Profile
Name
Omeros Corp
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
9.48 | 675.26M | 0 | 84.01M | -101.16M | 0.856 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corp Stock (OMER) Latest News
How Omeros shareholders can join the June 18 virtual annual meeting - Stock Titan
Omeros Announces Webcast Details for Annual Meeting of Shareholders - Yahoo Finance
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
OMER Stock Slides As Volatility Grabs Traders’ Attention - StocksToTrade
OMER Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
H.C. Wainwright reiterates Omeros stock rating at buy, $40 target - Investing.com
H.C. Wainwright reiterates Omeros stock rating at buy, $40 target By Investing.com - Investing.com South Africa
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now - Yahoo Finance
OMER Technical Analysis | Trend, Signals & Chart Patterns | OMEROS CORP (NASDAQ:OMER) - ChartMill
OMER Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold) - Seeking Alpha
Omeros (OMER) Q4 2025 Earnings Transcript - AOL.com
OMER Stock Chart | OMEROS CORP (NASDAQ:OMER) - ChartMill
Omeros Corp director Cable sells $87,039 in stock By Investing.com - Investing.com Australia
Omeros Corp director Cable sells $87,039 in stock - Investing.com
Omeros (NASDAQ: OMER) director exercises options and sells 7,500 shares under 10b5-1 plan - Stock Titan
Why Omeros Stock Is Sliding Today Even as Biotech Shares Climb - Bez Kabli
OMER Technical Analysis & Stock Price Forecast - Intellectia AI
Why did Omeros stock jump 5% in after-hours trading today? - MSN
[144] OMEROS CORP SEC Filing - Stock Titan
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA - MSN
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss - Investing.com
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss By Investing.com - Investing.com Canada
Omeros’ $100 Million Buyback Plan Heightens Volatility and Valuation Risk for Shareholders - The Globe and Mail
Seattle InnoSEngine headed to Bothell I An update on Omeros - The Business Journals
Omeros Corporation (NASDAQ:OMER) Q1 2026 Earnings Call Transcript - Insider Monkey
Omeros (OMER) Q1 2026 Earnings Transcript - The Globe and Mail
Omeros Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Omeros (OMER) Reports Strong Q1 2026 Earnings and Positive Cash Flow from YARTEMLEA - GuruFocus
Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YART - GuruFocus
OMER SWOT Analysis: Key Insights from Q1 2026 10-Q Filing - GuruFocus
Omeros Q1 Earnings Call Highlights - Barchart
How Should Investors Value Omeros (OMER) After Q1 2026 EPS $0.62 - GuruFocus
Omeros (OMER) Reports Q1 Revenue and Highlights Growth Initiativ - GuruFocus
Omeros Q1 2026 Earnings Call Transcript - MarketBeat
Omeros earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Omeros misses Q1 2026 expectations, stock dips - Investing.com
Omeros Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts - ChartMill
OMEROS ($OMER) Releases Q1 2026 Earnings - Quiver Quantitative
Q1 2026 Omeros Corp Earnings Call Transcript - GuruFocus
Omeros Corp Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omeros Corp Stock (OMER) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cable Thomas J. | Director |
May 22 '26 |
Sale |
11.61 |
7,500 |
87,039 |
35,067 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):